Nuuvera announced it entered a letter of intent to acquire the 49 percent minority interest in Avanti Rx Analytics.
Nuuvera (TSXV:NUU) announced it entered a letter of intent to acquire the 49 percent minority interest in Avanti Rx Analytics.
As quoted in the press release:
As part of the acquisition, the Company also anticipates acquiring Avanti’s facility at 135 Devon Road, Brampton, Ontario (together, the “Avanti Transaction“). Total consideration for the Avanti Transaction is expected to be approximately $43 million.
Ronald Schmeichel, Chairman of Nuuvera, said, “the acquisition of Avanti is an important step in the history of Nuuvera and is expected to result in synergies at the combined Nuuvera / Aphria which will enhance the value of the Arrangement to shareholders of Nuuvera.”